Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 17 articles:
HTML format
Text format



Single Articles


    June 2018
  1. GENOVESE MC, Fleischmann R, Combe B, Hall S, et al
    Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Lancet. 2018 Jun 12. pii: S0140-6736(18)31116.
    PubMed     Text format     Abstract available


  2. BURMESTER GR, Kremer JM, Van den Bosch F, Kivitz A, et al
    Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet. 2018 Jun 12. pii: S0140-6736(18)31115.
    PubMed     Text format     Abstract available


    June 2017
  3. SCOTT DL, Stevenson MD
    Treating active rheumatoid arthritis with Janus kinase inhibitors.
    Lancet. 2017 Jun 15. pii: S0140-6736(17)31659.
    PubMed     Text format    


  4. FLEISCHMANN R, Mysler E, Hall S, Kivitz AJ, et al
    Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Lancet. 2017 Jun 15. pii: S0140-6736(17)31618.
    PubMed     Text format     Abstract available


  5. BURMESTER GR, Pope JE
    Novel treatment strategies in rheumatoid arthritis.
    Lancet. 2017;389:2338-2348.
    PubMed     Text format     Abstract available


  6. MCINNES IB, Schett G
    Pathogenetic insights from the treatment of rheumatoid arthritis.
    Lancet. 2017;389:2328-2337.
    PubMed     Text format     Abstract available


  7. LANE R
    Gerd Burmester: enduring leader in rheumatoid arthritis.
    Lancet. 2017;389:2279.
    PubMed     Text format    


    February 2017
  8. FLEISCHMANN R
    Interleukin-6 inhibition for rheumatoid arthritis.
    Lancet. 2017 Feb 16. pii: S0140-6736(17)30405.
    PubMed     Text format    


  9. ALETAHA D, Bingham CO 3rd, Tanaka Y, Agarwal P, et al
    Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Lancet. 2017 Feb 15. pii: S0140-6736(17)30401.
    PubMed     Text format     Abstract available


    January 2017
  10. SEROR R, Mariette X
    Cost-effectiveness of rituximab strategies in rheumatoid arthritis.
    Lancet. 2017;389:365-366.
    PubMed     Text format    


    November 2016
  11. SMOLEN JS, Burmester GR, Combe B, Curtis JR, et al
    Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Lancet. 2016 Nov 11. pii: S0140-6736(16)31651.
    PubMed     Text format     Abstract available


    June 2016
  12. BIJLSMA JW, Welsing PM, Woodworth TG, Middelink LM, et al
    Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Lancet. 2016 Jun 7. pii: S0140-6736(16)30363.
    PubMed     Text format     Abstract available


  13. SCOTT DL
    Beyond methotrexate monotherapy for early rheumatoid arthritis.
    Lancet. 2016 Jun 7. pii: S0140-6736(16)30678.
    PubMed     Text format    


    May 2016
  14. HUIZINGA TW, Grondal G
    Drivers of costly treatment strategies in rheumatoid arthritis.
    Lancet. 2016 May 16. pii: S0140-6736(16)30548.
    PubMed     Text format    


  15. PORTER D, van Melckebeke J, Dale J, Messow CM, et al
    Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Lancet. 2016 May 16. pii: S0140-6736(16)00380.
    PubMed     Text format     Abstract available


  16. SMOLEN JS, Aletaha D, McInnes IB
    Rheumatoid arthritis.
    Lancet. 2016 May 3. pii: S0140-6736(16)30173.
    PubMed     Text format     Abstract available


    September 2015
  17. CAREY EJ, Ali AH, Lindor KD
    Primary biliary cirrhosis.
    Lancet. 2015 Sep 10. pii: S0140-6736(15)00154.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: